Tag:
Enanta
Latest Headlines
Latest Headlines
Enanta prices IPO shares at low end of range
The biotech priced its shares at the low end of the range, but Enanta is avoiding the deep discounting that was required for other biotechs to complete their maiden offering.
Aratana joins biotech IPO queue while Tetraphase takes a haircut
Aratana Therapeutics, which is developing six new treatments for cats and dogs, joined the biotech queue on Wall Street, filing an S-1 indicating a desire to raise $57.5 million in an IPO.
Enanta pins $73M IPO bid on a hot hep C blockbuster contender
The biotech has priced 4 million shares at $14 to $16 apiece, betting that its big role in a closely-watched hepatitis C study will provide enough cash to fund the developer for some time to come.
Abbott's interferon-free hep C combo wows in PhIIb test
Abbott Laboratories made a late entry into the red-hot race to develop an interferon-free approach to hepatitis C. But after playing catch-up with the likes of Gilead, it's now aiming for the inside track.
Defining 'fierce' in the modern age of drug and device development
Now, more than ever, the life sciences industry is all about innovative and disruptive technologies. Every year for the past decade, FierceBiotech has made its picks on which companies hold the best odds for success in our Fierce 15 report . This year, though, we've added another Fierce 15 to focus on medical devices and diagnostics. I'd like to encourage readers to consider the differences by comparing the companies in each report.
FierceBiotech's 2012 Fierce 15 at BioPharm America
Nick Leschly, the CEO of Bluebird Bio, playfully dubbed the ambitious spirit of biotechs Levin Syndrome, a fictional affliction named after Third Rock Ventures' Mark Levin that compels biotech entrepreneurs to, as they say, go big or go home. Our Fierce 15 companies are all "going big." They also went home… with trophies. Check out the slideshow below.
The Fierce 15: An appetite for risk is healthy in drug development
There's more than one way to build a biotech company. And this year's Fierce 15 companies reflect a range of companies operating with a spectrum of business models. Here's the full report >>
Click here to view a video of FierceBiotech Editor John Carroll announcing the Fierce 15 at BioPharm America >>
Novartis snags preclinical hep C drug in $440M Enanta pact
Novartis ( $NVS ) has signed a $440 million pact to license a preclinical NS5A drug from Enanta Pharmaceuticals.
Enanta lands $43M NIAID development contract
Watertown, MA-based Enanta Pharmaceuticals reports that it has won a 5-year development contract with the National Institute of Allergy and Infectious Diseases (NIAID) which will provide up to $42.7
